A few months ago I received a recommendation from someone in the industry so I bought AMRI at 18 and more in the mid 15s. Wasn't looking so great until the last few weeks. Today was ultra impressive as the breakout was on big volume.
If you owe Chuck a beer then I guess my friend also has one coming.
Food safety is an unsolved problem with an estimated 48 million foodborne illnesses occurring each year and costing over $50 billion.
PURE Bioscience is revolutionizing food safety with their heavily patented “SDC” and is positioned to become a leader in the food industry.
SDC has already been tested in several large restaurant chains and the results were significantly superior to all other methods. SDC is a powerful and extremely effective antimicrobial but it is safe to humans and has been granted the EPA’s safest product classification of a category IV.
LARGE RESTAURANT CHAINS are placing reorders that are expected to continue to increase to very sizeable numbers. PURE believes this is a 1.5 billion dollar market and SDC is far ahead of the competition.
Based on meetings with the USDA and the FDA, FOOD PROCESSORS are expected to be using SDC in 2015 to decontaminate produce and meat. SDC will also extend shelf life as well as reduce manufacturers costs. PURE believes this is billion-dollar market.
No other product can do what SDC does and do it safely.
SDC will dominate antimicrobials in hospitals, schools, homes, offices, markets, public places, cruise ships, airplanes, trains, personal products like soaps and everywhere the public gathers. Antimicrobial market for disease protection such as influenza, MRSA, etc. is another multi-billion dollar market
SDC is perfectly safe and it continues to kill dangerous pathogens for 24 hours EVEN AFTER IT DRIES.
PURE Bioscience is on the verge of delivering very large and fast growing revenues beginning this year and shares are trading between $1.10 and $1.20 with a very small market cap of $32 million.
All this information can be confirmed on YAHOO FINANCE under “PURE”
PURE is a Strong Buy and Hold
Sentiment: Strong Buy
From a WSJ story today titled, Drug Delays Cost U.S. Health-Care Payers Millions of Dollars: “Many of Ranbaxy's Indian factories are now effectively mothballed after manufacturing concerns. Just one of its plants, located in New Jersey, is now producing drugs for U.S. consumption. Ranbaxy could potentially sidestep its manufacturing problems by outsourcing production or sourcing ingredients from rivals.”
“Outsourcing production” –I like the sound of that! If they do, I hope they choose AMRI as their partner.
Today's Barron's featured a recommendation by Oscar Schafer in the mid-year Roundtable article, and also a report in the Market Week section saying that Morgan Stanley increased their target price for AMRI to $21 from $19, and continues to rate it "overweight."
“Bid for Allergan Puts Valeant's Research and Development Cuts Under Scrutiny” – Here’s an excerpt relevant to AMRI: . . . “big companies still spend billions of dollars on their own research, while also doing more deals to fill up their pipelines with drugs discovered at smaller companies and labs.”
PURE Bioscience (PURE) found a new use for biotech that can quickly and safely kill pathogens that are dangerous to humans such as MRSA, influenza, HIV, E.coli, Salmonella, Norovirus, Hepatitis, Pneumonia, colds, Polio, deadly fungus, and most common infectious diseases.
AND THE SOLUTION IS SAFE, FAST, CHEAP AND EASY.
PURE Bioscience developed HEAVILY PATENTED “SDC” THAT KILLS ALL THE ABOVE-MENTIONED PATHOGENS AND YET IS PERFECTLY SAFE.
SDC is Silver Dihydrogen Citrate that has been infused with negative ions.
IT IS SIMPLY WIPED OR SPRAYED ON ANY SURFACE AND IT REMAINS ACTIVE FOR 24 HOURS.
Over 650 restaurants tested SDC on more than 1,000 data points and compared the efficacy of the chain's current sanitizer with that of PURE Hard Surface disinfectant and sanitizer and SDC was OVER 90% MORE EFFECTIVE.
SDC has also been successfully tested for food processing of meats and produce to destroy the dangerous pathogens such as E.coli, Salmonella, Norovirus and others and is expected to set the standard in the food industry.
THE EPA CLASSIFIES SDC WITH THEIR SAFEST RATING OF CATEGORY IV.
Also important is that SDC does not cause these dangerous pathogens to become resistant the way antibiotics does.
The World Health Organization estimates the cost of influenza epidemics to the economy at $71-167 billion per year.
The CDC estimates that each year, 48 million food borne illnesses from contaminated foods result in over $50 billion in losses from 128,000 hospitalizations, 3,000 deaths and very costly food recalls and lawsuits.
SDC will appeal to large markets such as the cruise industry, air travel, all public transportation, schools, hospitals, sporting events and essentially ALL PUBLIC PLACES.
SDC SALES ARE POSITIONED TO EXPLODE and PURE shares are only $1.20.
Sentiment: Strong Buy